Three BLAs, Three Journeys, with Irving Ford, Megan Callan, and Jake Treese

Episode 12

0:00-34:54

Three BLAs. Three companies. One industry-defining challenge. Jake Trees, Irving Ford, and Megan Callan on What It Really Takes to Cross the Commercial Line in Cell and Gene Therapy In this special compiled episode of Let's Talk Quality, Hemish Ilangaratne brings together three quality leaders who have each led their organisation through one of the most demanding transitions in the industry: from clinical development to commercial manufacturing for a cell or gene therapy product. Jake Trees spent five years at Bristol Myers Squibb leading the quality function through the approval and launch of Abecma and Breyanzi, two of the first commercially approved CAR T cell therapies in the world. Irving Ford was the first quality hire at the Celgene cell therapy facility in New Jersey, built the QC organisation from nothing, and has since led quality through four BLA approvals across multiple cell therapy companies, most recently at Adaptimmune for the approval of Aucatzyl. Megan Callan is VP of Quality at Abeona Therapeutics, where she guided the quality team through the FDA approval of Zevaskyn, the first ever approved topical gene therapy for a rare genetic skin disorder. These are three distinct products, three distinct companies, and three distinct leadership journeys.

Publisher

Let's Talk Quality

Link

rx-group.io/captivate-podcast/three-blas-three-journeys-with-irving-ford-megan-callan-and-jake-treese

Published

May 7, 2026

Duration

35 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

Hemish Ilangaratne

LT

Let's Talk Quality

@letstalkquality

#irvingford #megancallan #jaketreese #lifesciences #careers #management

The Nile